Thymosin Alpha-1

Thymosin alpha-1 (Ta1) is a 28-amino-acid peptide cleaved from its 113-residue precursor prothymosin alpha within the thymus, carrying an N-terminal acetyl group and a molecular weight of approximately 3,108 daltons.

At the molecular level, Ta1 acts as a toll-like receptor (TLR) agonist, engaging TLR-2, TLR-3, TLR-4, and TLR-9 expressed on myeloid and plasmacytoid dendritic cells. Receptor engagement activates the downstream transcription factors IRF3 and NF-kB, driving production of type I interferons (IFN-alpha), IL-12, IL-2, and IL-10 while concurrently suppressing IL-1beta and tumor necrosis factor-alpha. This dual immunomodulatory profile restores immune balance rather than producing nonselective stimulation.

Ta1 promotes differentiation of T-cell precursors into mature CD4+ helper and CD8+ cytotoxic subsets, augments natural killer cell cytotoxic activity, and upregulates major histocompatibility complex class I expression on infected cells, improving viral antigen presentation to cytotoxic lymphocytes. In lymphopenic patients, thymus output—as measured by T-cell receptor excision circles in peripheral blood mononuclear cells—rises following Ta1 administration, consistent with partial restoration of de novo T-cell production.

Because the thymus involutes progressively with age, endogenous Ta1 levels decline across the lifespan. Exogenous administration is proposed to compensate for age-related immunosenescence and for the secondary immunosuppression associated with chronic infection or malignancy.

The strongest clinical evidence for Ta1 spans chronic hepatitis B and C, sepsis, and non-small cell lung cancer (NSCLC), with smaller and more conflicting data in COVID-19 and other infections.

Hepatitis B: A multicentre, double-blind, placebo-controlled Phase III trial (n = 97) randomised HBeAg- and HBV DNA-positive patients to 1.6 mg subcutaneous Ta1 or placebo twice weekly for six months. Complete virological response was observed in 14% of treated patients versus 4% on placebo (p = 0.084), a trend that failed to reach statistical significance. Pooled data from earlier trials cited in the Zadaxin prescribing dossier indicated a 36% monotherapy response rate versus 19% for placebo. In hepatitis C, Ta1 combined with interferon-alpha produced a 22.4% sustained virological response versus 9.3% with interferon alone.

Sepsis: A 2025 systematic review and meta-analysis (n = 1,972 across multiple randomised controlled trials) found that adjunctive Ta1 reduced 28-day all-cause mortality (RR 0.77, 95% CI 0.59-0.99, p = 0.04) and ICU mortality (RR 0.76), and decreased mechanical ventilation duration by a mean 1.80 days (p = 0.03). Heterogeneity across trials was present and the authors called for confirmatory large trials.

NSCLC: A meta-analysis of 27 RCTs (1,925 patients, predominantly Chinese) found that adding synthetic thymic peptides—primarily Ta1—to platinum-based chemotherapy improved objective response rate (RR 1.28, 95% CI 1.13-1.45), disease control rate (RR 1.10), quality of life (RR 2.05), and one-year overall survival (RR 1.43, 95% CI 1.15-1.78), with reduced rates of neutropenia and gastrointestinal toxicity. Overall evidence quality was rated moderate to very low.

COVID-19: A retrospective study of 76 severely ill Wuhan patients found lower mortality in the Ta1 group (11.1% vs 30.0%, p = 0.044) and reduced PD-1 and Tim-3 expression on exhausted CD8+ T cells. A separate retrospective study of 275 Shanghai patients found no significant improvement in CD4+ or CD8+ T lymphocyte restoration, leaving COVID-19 evidence preliminary and internally conflicting.

Typical dosage: 1.6-3.2 mg (twice-weekly).

The standard clinical dosage studied in randomised trials is 1.6 mg (approximately 900 mcg/m2) administered by subcutaneous injection twice weekly, with doses separated by approximately 3 to 4 days (for example, Monday and Thursday). This regimen is typically continued for 6 to 12 months depending on indication. Patients weighing less than 40 kg receive weight-based dosing of 40 mcg/kg.

In critical care settings (sepsis), shorter and more intensive courses have been used: doses ranging from 1.6 to 16 mg administered over 5 to 7 days as an adjunct to standard treatment. Chinese clinical protocols exploring severe COVID-19 treatment used up to 10 mg/day by intramuscular injection for at least 7 consecutive days; these higher-dose regimens lack the level of controlled evidence supporting the established hepatitis and sepsis protocols.

The compound is dispensed as a lyophilised powder requiring reconstitution with supplied sterile water immediately before injection. Reconstituted solution should be administered promptly; if refrigerated storage is necessary, stability at 4 degrees C is limited to approximately 2 to 7 days depending on the formulation. The peptide is not orally bioavailable; all studied routes are injectable.

Thymosin alpha-1 is not FDA-approved in the United States for any indication. As of early 2026, the FDA placed it in Category 2 status under the 503A compounding framework following a Pharmacy Compounding Advisory Committee review; current US availability through compounding pharmacies should be independently verified against the most current regulatory guidance.

This information is provided for educational reference only and does not constitute medical advice. Dosing should be determined and supervised by a qualified healthcare provider.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

Clinically studied combinations include:

• Hepatitis B and C: Ta1 combined with interferon-alpha (including pegylated interferon-alpha-2a) was studied in multiple trials. Pooled data suggest additive virological response rates, although this evidence predates modern direct-acting antivirals and involves relatively small sample sizes.

• NSCLC: Combination with platinum-based doublet chemotherapy (cisplatin plus vinorelbine or gemcitabine) was the model for the 27-trial meta-analysis, which showed improved response rates and reduced chemotherapy-related toxicity compared with chemotherapy alone.

• Sepsis: Ta1 as adjunct to standard intensive care (antibiotics, vasopressors, organ support) represents the combination context of the 1,972-patient meta-analysis.

• Immune checkpoint inhibitors: Emerging early clinical and preclinical work proposes combining Ta1 with PD-1/PD-L1 inhibitors in oncology, on the rationale that Ta1 activates T cells while checkpoint blockade prevents their re-exhaustion. Evidence is preliminary; no completed phase III data exist as of mid-2026.

• Other peptides (e.g., thymosin beta-4, BPC-157): Ta1 is sometimes co-administered with tissue-repair peptides in compounding clinic and biohacking contexts. This practice is entirely anecdotal; no published controlled evidence supports these multi-peptide combinations.

Thymosin Alpha-1 is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Well-tolerated. Rare: injection site reactions, mild flu-like symptoms

In controlled trials and clinical series encompassing more than 3,000 treated individuals—including patients with hepatocellular carcinoma, NSCLC, melanoma, and chronic hepatitis B and C—thymosin alpha-1 has demonstrated a consistently favorable safety profile. The most common adverse events are mild localized discomfort, erythema, and tenderness at the subcutaneous injection site. Systemic reactions—including transient fever, fatigue, myalgia, nausea, and vomiting—are reported infrequently and are typically self-limiting.

Rare adverse reactions documented in clinical series include polyarthralgia with hand edema, transient localized muscle atrophy at the injection site, skin rash, and rare neutropenia.

The primary contraindication is deliberate immunosuppression: Ta1 should not be administered to organ transplant recipients or others in whom amplification of T-cell and dendritic cell activity risks graft rejection or other immune-mediated harm, unless the clinical benefit is judged to clearly outweigh the risk.

Safety in pediatric populations has not been established in controlled studies. Data in pregnancy and lactation are absent from the published literature. Hypersensitivity to Ta1 or any component of the injection formulation is a contraindication.

Internationally, thymalfasin (brand name Zadaxin) holds regulatory approval in more than 35 countries including China, where it is indicated for chronic hepatitis B, chronic hepatitis C, and as adjunctive cancer immunotherapy. It is not approved by the US Food and Drug Administration. As of early 2026, the FDA's Pharmacy Compounding Advisory Committee review moved Ta1 to Category 2 status under 503A bulk drug substance regulations, effectively restricting its compounding availability in the US.